Literature DB >> 21116832

Natural history of renal cell carcinoma: a case with 18 years follow-up.

Fumitake Kai1, Tatsuya Takayama, Toshiki Ito, Shinsuke Hadano, Seiichiro Ozono.   

Abstract

A 53-year-old woman presented to our hospital with a non-metastatic 4 cm renal mass in the right kidney. The patient rejected treatment, but consented to follow-up observation of her condition. The patient underwent a series of computed tomography scans to monitor the progression of the disease. We were able to observe not only an increase in renal mass size, but also involvement of para-aortic lymph nodes, inferior vena cava, and metastasis to the lung. Eighteen years after diagnosis, the subject was hospitalized and died as a result of complications of the disease. Autopsy showed the pathologic diagnosis of the renal mass to be a grade 2 clear cell carcinoma. The literature contains several papers that describe the natural history of renal masses and carcinomas over short periods; however, prior to our case, no reports existed that detailed long-term progression of renal cell carcinoma (RCC) from initial diagnosis to death. It is necessary to clarify the course that RCC takes due to its unpredictable, indolent nature. This will provide clinicians with better insight into how to manage the disease, decide on treatment options, and improve overall survival.

Entities:  

Mesh:

Year:  2010        PMID: 21116832     DOI: 10.1007/s10157-010-0383-z

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  14 in total

1.  Watchful waiting for solid renal masses: insight into the natural history and results of delayed intervention.

Authors:  Erik Kouba; Angela Smith; Daniel McRackan; Eric M Wallen; Raj S Pruthi
Journal:  J Urol       Date:  2007-02       Impact factor: 7.450

2.  The natural history of small renal masses.

Authors:  R A Rendon; N Stanietzky; T Panzarella; M Robinette; L H Klotz; W Thurston; M A Jewett
Journal:  J Urol       Date:  2000-10       Impact factor: 7.450

3.  Growth rates of primary and metastatic lesions of renal cell carcinoma.

Authors:  T Oda; N Miyao; A Takahashi; M Yanase; N Masumori; N Itoh; M Tamakawa; T Tsukamoto
Journal:  Int J Urol       Date:  2001-09       Impact factor: 3.369

Review 4.  Renal tumor natural history: the rationale and role for active surveillance.

Authors:  Michael A S Jewett; Alvaro Zuniga
Journal:  Urol Clin North Am       Date:  2008-11       Impact factor: 2.241

5.  Natural history of renal masses followed expectantly.

Authors:  W Kassouf; A G Aprikian; M Laplante; S Tanguay
Journal:  J Urol       Date:  2004-01       Impact factor: 7.450

6.  Natural history of small renal cell carcinoma: evaluation of growth rate, histological grade, cell proliferation and apoptosis.

Authors:  Masanori Kato; Takashi Suzuki; Yasuyoshi Suzuki; Yoshio Terasawa; Hironobu Sasano; Yoichi Arai
Journal:  J Urol       Date:  2004-09       Impact factor: 7.450

7.  Volume doubling time and growth rate of renal cell carcinoma determined by helical CT: a single-institution experience.

Authors:  Ji Young Lee; Chan Kyo Kim; Dongil Choi; Byung Kwan Park
Journal:  Eur Radiol       Date:  2007-12-11       Impact factor: 5.315

Review 8.  Is surveillance an option for the treatment of small renal masses?

Authors:  Hendrik Van Poppel; Steven Joniau
Journal:  Eur Urol       Date:  2007-07-23       Impact factor: 20.096

9.  Tumor doubling time of renal cell carcinoma measured by CT: collaboration of Japanese Society of Renal Cancer.

Authors:  Seiichiro Ozono; Noriomi Miyao; Tatsuo Igarashi; Ken Marumo; Hayakazu Nakazawa; Momokuni Fukuda; Tomoyasu Tsushima; Noriaki Tokuda; Juichi Kawamura; Masaru Murai
Journal:  Jpn J Clin Oncol       Date:  2004-02       Impact factor: 3.019

10.  Active surveillance for selected patients with renal masses: updated results with long-term follow-up.

Authors:  Tamer Abou Youssif; Wassim Kassouf; Jordan Steinberg; Armen G Aprikian; Micheal P Laplante; Simon Tanguay
Journal:  Cancer       Date:  2007-09-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.